Key result
Multimodality therapy for head and neck Ewing sarcoma yields ~86% 7-year survival with comparable local control.
Why the study?
Ewing sarcoma of the head and neck is rare, and optimal management remains uncertain.
What are the long-term outcomes of multimodality therapy for head and neck Ewing sarcoma?
Cohort (n=102)
No
What are the long-term outcomes of multimodality therapy for head and neck Ewing sarcoma?
Answers are grounded in this paper and cite their sources.
Multimodality therapy for head and neck Ewing sarcoma yields favorable long-term outcomes, with definitive radiotherapy being an appropriate alternative when surgery is infeasible.
ABSTRACT Purpose Ewing sarcoma (ES) of the head and neck is rare, and optimal management remains uncertain. We evaluated outcomes of patients treated with curative intent using a uniform multimodality protocol at our institute. Materials and Methods Between January 2005 and December 2020, 102 patients with histologically confirmed head and neck ES were retrospectively analysed. Median age was 14 years (range, 2 months–42 years), and median tumour size was 5cm (range, 2–12cm). All patients received systemic chemotherapy (CTh) combined with local therapy: surgery (n=10), radiotherapy (RT) alone (n=44), or surgery followed by RT (n=47), followed by maintenance chemotherapy. RT alone was offered when surgery was infeasible or associated with significant morbidity. Survival outcomes, prognostic factors, failure patterns, and toxicity were assessed. Results One patient died during induction chemotherapy. At a median follow-up of 79 months, 7-year local control (LC), event-free survival (EFS), and overall survival (OS) were 81.2%, 73.2%, and 86.2%, respectively. LC did not significantly differ by local modality (surgery vs RT vs surgery + RT: 87.5% vs 71.9% vs 88.2%; p=0.34). On univariable analysis, metastatic status, anaemia, elevated platelet-to-lymphocyte ratio, local modality, R1 resection, and partial RT response predicted OS. Failures included isolated local relapse (n=9), distant metastases (n=9), and combined relapse (n=6). Conclusion Multimodality therapy yields favourable long-term outcomes with acceptable toxicity. Surgery should be considered when feasible, with adjuvant RT as indicated. Definitive RT remains appropriate for unresectable disease.
No takes yet. Share an insight, caveat, or question.
Krishnan et al. (2026) conducted a cohort in Ewing sarcoma of the head and neck (n=102). Multimodality therapy (systemic chemotherapy combined with local therapy) was evaluated on 7-year overall survival (OS). Multimodality therapy for head and neck Ewing sarcoma yielded a 7-year overall survival of 86.2%, with no significant difference in local control between local modalities.
Synapse has enriched 10 related papers. Consider them for comparative context: